Deaths not increased with Avastin

Despite previous claims, bevacizumab (Avastin) does not appear to increase deaths or serious side-effects compared with ranibizumab (Lucentis) in people with neovascular age-related macular degeneration.

The findings came from a Cochrane Review of nine studies (total 3665 participants).

The systematic review of non-industry sponsored randomised trials “could not determine a difference between intra-vitreal bevacizumab and ranibizumab for deaths, all serious systemic adverse events (SSAEs), or